Trend analysis of carbapenem-resistant Gram-negative bacteria and antimicrobial consumption in the post-COVID-19 era: an extra challenge for healthcare institutions.

de Carvalho Hessel Dias, V M; Tuon, F; de Jesus Capelo, P; Telles, J P; Fortaleza, C M C B; Pellegrino Baena, C

de Carvalho Hessel Dias, V M; Tuon, F; de Jesus Capelo, P; Telles, J P; Fortaleza, C M C B; Pellegrino Baena, C.

Afiliación

de Carvalho Hessel Dias VM; School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil; Hospital Marcelino Champagnat, Curitiba, Paraná, Brazil. Electronic address: carvalhohdias@gmail.com.
Tuon F; Laboratory of Emerging Infectious Diseases, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil.
de Jesus Capelo P; State Health Department of Paraná, Curitiba, Paraná, Brazil.
Telles JP; School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil.
Fortaleza CMCB; Universidade Estadual Paulista (UNESP), Botucatu, Sao Paulo, Brazil.
Pellegrino Baena C; School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil; Hospital Marcelino Champagnat, Curitiba, Paraná, Brazil.

J Hosp Infect ; 120: 43-47, 2022 Feb.

Article en En | MEDLINE | ID: mdl-34808311

Asunto(s)

Acinetobacter baumannii; Antiinfecciosos; COVID-19; Antibacterianos/farmacología; Antibacterianos/uso terapéutico; Carbapenémicos; Atención a la Salud; Farmacorresistencia Bacteriana; Bacterias Gramnegativas; Humanos; Pruebas de Sensibilidad Microbiana; SARS-CoV-2

Palabras clave

Acinetobacter baumannii; Antimicrobial drug resistance; COVID-19; Carbapenems; Healthcare-associated infections; Polymyxins

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Acinetobacter baumannii / COVID-19 / Antiinfecciosos Límite: Humans Idioma: En Revista: J Hosp Infect Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google